Azenta, Inc.
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Produc…
Medical - Instruments & Supplies
US, Chelmsford [HQ]
Insiders
Transactions
Track non-derivative insider transactions.
i = Indirect Ownership
d = Direct Ownership
cs = Common Stock
| Reported Owner(s) | Position Now | Transaction Date | Type | Position Change | Extra | ||
|---|---|---|---|---|---|---|---|
|
$35,313
d
Common
10% Holder
|
12/05/24 |
A
|
5,768 x $45.00 = $259,560.00 |
Footnotes
#1 Represents two grants of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan, one grant of 23,045 units subject to time-based vesting and will vest 33% per year for three years, beginning on December 5, 2025 and another grant of 5,768 units subject to time-based vesting and will vest 50% per year for two years, beginning on December 5, 2025. No amount was paid upon grant of the units.
|
|||
|
$29,545
d
Common
10% Holder
|
12/05/24 |
A
|
23,045 x $45.00 = $1,037,025.00 |
Footnotes
#1 Represents two grants of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan, one grant of 23,045 units subject to time-based vesting and will vest 33% per year for three years, beginning on December 5, 2025 and another grant of 5,768 units subject to time-based vesting and will vest 50% per year for two years, beginning on December 5, 2025. No amount was paid upon grant of the units.
|
|||
|
$23,974
d
Common
10% Holder
|
12/04/24 |
D
|
140 x $46.65 = $6,531.00 |
Footnotes
#1 The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on December 2, 2024 of 470 restricted stock units held by the reporting person.
|
|||
|
$9,920
d
Common
10% Holder
|
11/19/24 |
S
|
163 x $40.07 = $6,531.41 |
Footnotes
#1 Represents the sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2024 of 459 restricted stock units from one grant held by the reporting person and previously reported on Form 4.
#2 Represents the weighted average price for shares sold between November 18, 2024 and November 19, 2024 at a range between $38.83 and $41.48. The reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
|
|||
|
$19,373
d
Common
10% Holder
|
11/19/24 |
S
|
548 x $40.07 = $21,958.36 |
Footnotes
#1 Represents the sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2024 of 1,069 restricted stock units from one grant held by the reporting person and previously reported on Form 4.
#2 Represents the weighted average price for shares sold between November 18, 2024 and November 19, 2024 at a range between $38.83 and $41.48. The reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
|
|||
Get PRO Today
With PRO you will unlock 46 more insider transactions for Azenta, Inc.
Statistics
Sample Size: 51 Transactions
Sale (S)
4,996 Shares
13.73%
Buy (P)
12,736,667 Shares
9.80%
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Bousa Edward Peter Director
- Casal Frank Director
- Cornog William L Director
- Cueto Herman Interim CFO
- Davis Robyn C Director
- Hirsch Didier Director
- Hughes Violetta VP, Chief Accounting Officer
- Joseph Jason SVP, General Counsel, Secy.
- Koffey Quentin Director
- Lin Lawrence Y. EVP, CFO and Treasurer
- Madaus Martin D Director
- Malus Alan J Director
- Marotta John President and CEO
- Mclaughlin Erica Executive Vice President, CFO
- Nova Tina Susan Director
- Pirogova Olga SVP and CHRO
- Rosenblatt Michael Director
- Vacha Robin SVP, GM Life Science Products
- Wang David Dong SVP & GM, SMS
- Zhou Ginger SVP and General Manager, Genom
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Bousa Edward Peter Director
- Casal Frank Director
- Cornog William L Director
- Cueto Herman Interim CFO
- Davis Robyn C Director
- Hirsch Didier Director
- Hughes Violetta VP, Chief Accounting Officer
- Joseph Jason SVP, General Counsel, Secy.
- Koffey Quentin Director
- Lin Lawrence Y. EVP, CFO and Treasurer
- Madaus Martin D Director
- Malus Alan J Director
- Marotta John President and CEO
- Mclaughlin Erica Executive Vice President, CFO
- Nova Tina Susan Director
- Pirogova Olga SVP and CHRO
- Rosenblatt Michael Director
- Vacha Robin SVP, GM Life Science Products
- Wang David Dong SVP & GM, SMS
- Zhou Ginger SVP and General Manager, Genom